
The AlphaLISA™ HP Human IL-6 kit is designed for the simple and rapid quantification of soluble IL-6 in cell supernatants and serum samples, offering a fast no-wash alternative to traditional wash-based ELISA. This kit is a new and improved version of the AL223 kit.
Feature | Specification |
---|---|
Protocol Time | 1.5h at RT |
Sample Volume | 10 µL |
The AlphaLISA™ HP Human IL-6 kit is designed for the simple and rapid quantification of soluble IL-6 in cell supernatants and serum samples, offering a fast no-wash alternative to traditional wash-based ELISA. This kit is a new and improved version of the AL223 kit.
IL6 is a pro-inflammatory cytokine involved in acute-phase reaction, inflammation, and cancer progression. Secreted by T cells, macrophages, and fibroblasts, it induces B and T cell proliferation. It is being studied in a wide variety of research areas including diabetes, Alzheimer's disease, depression, and several cancers. Along with TGF beta, IL6 is main promoter of T cell differentiation into TH17, a new component of immuno-oncology. AlphaLISA assays may have sufficient sensitivity to enable detection of low levels of analytes in serum or plasma.
Formats
Features
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Automation Compatible |
Yes
|
---|---|
Brand |
AlphaLISA
|
Detection Modality |
Alpha
|
Protocol Time |
1.5h at RT
|
Sample Volume |
10 µL
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
IL-6
|
Target Class |
Cytokines
|
Target Species |
Human
|
Technology |
Alpha
|
Therapeutic Area |
Inflammation
|
Unit Size |
100 assay points
|
The AlphaLISA HP IL-6 assay is based on an AlphaLISA sandwich immunoassay involving a biotinylated anti-IL-6 antibody bound to Streptavidin-coated AlphaLISA Donor beads and an anti-IL-6 antibody conjugated to AlphaLISA Acceptor beads. Both antibodies are directed against the IL-6 protein. In the presence of the target, both antibodies bind to IL-6 and the beads come into proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer within the Acceptor beads, resulting in emission with λmax at 615 nm. The intensity of the signal is directly proportional to the concentration of IL-6 present in the sample.
The AlphaLISA HP Human IL-6 assay can be run in a 96- or 384-well detection plate (50 µL final). As described here, samples (cell supernatants or serum) or standards are dispensed directly into the assay plate for the detection of IL-6 by AlphaLISA reagents. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.
Time to result | 1.5 hours at RT |
---|---|
Kit component | Lyophilized IL-6 analyte, SA-Donor Beads, Biotinylated anti-IL-6, IL-6 conjugated Acceptor Beads, Assay Buffer |
Species | Human only |
LDL | 0.3 pg/mL |
LLOQ | 0.8 pg/mL |
Dynamic Range | 0.1-30,000 pg/mL |
Calibration | 1 unit (IU) of standard NIBSC (21/308) /WHO is equivalent to 0.42 pg of AlphaLISA hIL-6 |
Each of the 3 samples was measured 24 times, and the % CV was calculated for each sample. Samples were PBMC supernatants.
Sample | [IL-6] (pg/mL) | CV |
---|---|---|
1 | 4238 | 4.8% |
2 | 2309 | 7.1% |
3 | 364 | 11.9% |
Mean CV | 7.9% |
Each of the samples was measured in 3 independent experiments (3 days), and the % CV was calculated for each sample. Samples were MonoMac6 cell supernatants.
Sample | [IL-6] (pg/mL) | CV |
---|---|---|
1 | 2,100 | 13% |
2 | 1,370 | 14% |
3 | 250 | 12% |
Mean CV | 13% |
Each of the samples was measured in 3 independent experiments (3 days), and the % CV was calculated for each sample. Samples were PBMC cell supernatants.
Spiked IL-6 (pg/mL) |
% Recovery |
||
---|---|---|---|
DMEM+10% FBS | RPMI+10% FBS | 100% FBS | |
300 | 99% | 101% | 99% |
400 | 107% | 97% | 111% |
800 | 93% | 106% | 98% |
Each of the samples was measured in 3 independent experiments (3 days), and the % CV was calculated for each sample. Samples were PBMC supernatants.
Sample dilution factor (x) | Expected IL-6 (pg/mL) | Observed IL-6 (pg/mL) | Dilution recovery (%) |
---|---|---|---|
neat | 1460 | 1460 | 100% |
1/2 | 730 | 692 | 105% |
1/4 | 365 | 323 | 113% |
1/8 | 182 | 168 | 109% |
1/16 | 91 | 83 | 109% |
1/32 | 46 | 42 | 109% |
MonoMac6 (MM6) cells were plated at 10,000 per well (RPMI, 2% FBS) and stimulated with increasing concentrations of Reference Standard Endotoxin (RSE) at 37°C, 5%CO2. After 24h stimulation, the cell supernatant was collected and 5 µL of each samples were transferred into a n AlphaPlate-384 to measure the secreted IL-6 in each sample. The concentration of IL-6 in each sample was interpolated from a standard curve prepared in RPMI, 2% FBS.
Concentration (IU/mL) | |
---|---|
LLD | 0.020 |
LLOQ | 0.042 |
Are you looking for resources, click on the resource type to explore further.
We are here to answer your questions.